{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/06/01/3304230/0/en/Immuneering-Presents-Compelling-17-3-Month-Median-Overall-Survival-and-Favorable-Tolerability-with-Atebimetinib-Chemotherapy-in-First-Line-Pancreatic-Cancer-Patients-at-ASCO.html", "message": "News view counter 769638 successfully enlarged"}